Bupa has introduced a pharmacogenomics testing program for its health insurance customers in Australia, making genetic screening available to eligible members at no cost until the end of 2025.
This initiative, developed in partnership with myDNA, allows customers to access testing through Bupa’s digital health service, Blua, or at Bupa Medical Centres. The general public can also participate at a reduced price via Blua.
Pharmacogenomics examines how a person’s genetic makeup can influence their response to various medications.
The test analyses 11 genes that affect reactions to more than 100 commonly prescribed drugs, including those for mental health, cardiovascular conditions, cholesterol, and pain management.
The process involves a cheek swab, which customers can perform at home. Results are sent directly to the customer’s nominated general practitioner (GP), who will review the findings during a standard consultation.
According to Bupa, the purpose of the pharmacogenomics program is to equip clinicians with additional information to support medication decisions.
Dr Simon Benson, clinical innovation and genomics director at Bupa, stated that “pharmacogenomic testing can help inform medication choices, reduce side effects, and limit unnecessary healthcare cost.”
He added that pharmacogenomics offers data that can assist both healthcare professionals and patients in determining how a person might react to specific medications, thereby supporting more tailored treatment choices.
Bupa clarified that participation in the program does not affect members’ health insurance premiums, and individual test results will not be shared with the insurer.
The company also highlighted that the pharmacogenomic profile remains unchanged throughout a person’s life, allowing results to inform both current and future treatment decisions.
GPs may use the test outcomes to adjust dosages, switch medications, or modify treatment plans. Other considerations, such as a patient’s age, lifestyle, and concurrent medications, will continue to play a role in prescribing decisions.
Bupa anticipates that the program could help reduce avoidable hospital admissions and repeat GP visits related to medication issues.
Benson said individuals should review their pharmacogenetic test results with their GP as part of their overall care strategy.
“Finding the right medication and reducing side effects with guidance from healthcare professionals can potentially help increase patient adherence to treatment plans and contribute to improved health outcomes,” he said.
Allan Sheffield, co-founder of myDNA, said: “We firmly believe that pharmacogenomics testing should be a standard part of care for all Australians, which could help doctors provide more effective, personalised health outcomes.”
The offer is open to Bupa Health Insurance members aged 18 and over, with a cap of 10,000 free kits. Orders must be placed by Nov. 30, and samples returned by Dec. 31. The cost of GP consultations to discuss results is not included in the program.
The launch comes after the Bupa Foundation announced an expansion of its Community Grants program for this year, allocating over $600,000 to 65 organisations across Australia and New Zealand.
The grants are intended to support projects focused on mental health and sustainability, continuing the foundation’s emphasis on improving local health outcomes.
Since its inception in 2019, the Bupa Foundation has distributed more than $2.5 million to grassroots groups in the region.
The 2025 round marks the largest number of grant recipients to date, with a focus on practical, community-driven approaches to health and wellbeing.
